Cynthia (Cindy) Collins, is a recognized leader in cell and gene therapy, genomic medicine, molecular diagnostics, life sciences, and therapeutics. Prior to her most recent position as CEO of Editas Medicine (Nasdaq:EDIT), she served as CEO of Human Longevity Inc, a genomics-based company.  Prior to Human Longevity Cindy served as CEO/GM of General Electric’s Healthcare Cell Therapy Business, Lab Businesses, and Clarient Diagnostics. Before GE, Cindy served as CEO of GenVec (Nasdaq:GNVC) and Group Vice President, Cellular Analysis Business of Beckman Coulter. Prior to Beckman Coulter, she served as CEO of Sequoia Pharmaceuticals. Earlier, Cindy served as President of Clinical Micro Sensors, a subsidiary of Motorola. Prior to Motorola, she spent seventeen years with Baxter Healthcare and six years with Abbott Laboratories.  Cindy received her BS degree in Microbiology from the University of Illinois, Urbana and her MBA, from The University of Chicago Booth School of Business. Cindy is a member of the board of directors of DermTech (Nasdaq:DMTKQ), Certara (Nasdaq:CERT), Poseida Therapeutics (Nasdaq:PSTX), MaxCyte (Nasdaq:MXCT), Charles Draper Laboratory, Nutcracker Therapeutics, and Alanis Therapeutics.